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ABSTRACT 
 
Diseases in the ocular posterior segment are a leading cause of blindness. The surgical skills 
required to treat them are at the limits of human manipulation ability, and involve the risk of 
permanent retinal damage. Instrument tethering and design limit accessibility within the eye. 
Wireless microrobots suturelessly injected into the posterior segment, steered using magnetic 
manipulation, are proposed for procedures involving implantation. Biocompatibility is a 
prerequisite for these procedures. This paper investigates the use of cobalt-nickel microrobots 
coated with polypyrrole, and gold, which has been used as an ocular implant material. 
Polypyrrole has well-established biocompatibility properties, but no reports concerning its 
ocular implantation is available. Coated and uncoated microrobots were investigated for their 
corrosion properties, and solutions that had contained coated and uncoated microrobots for 
one week were tested for cytotoxicity by monitoring NIH3T3 cell viability. None of the 
microrobots showed significant corrosion currents and corrosion potentials were as expected 
in relation to the intrinsic nobility of the materials. NIH3T3 cell viability was not affected by 
the release medium, in which coated/uncoated microrobots were stored. In vivo tests inside 
rabbit eyes were performed using coated microrobots. There were no significant 
inflammatory responses during the first week after injection. An inflammatory response 
detected after two weeks was likely due to a lack of longer-duration biocompatibility. The 
results provide valuable information for those who work on implant technology and 
biocompatibility. Coated microrobots have the potential to facilitate a new generation of 
surgical treatments, diagnostics and drug-delivery techniques, when implantation in the 
ocular posterior segment will be possible. 
 
Keywords: ophthalmic microrobots, biocompatibility, corrosion, cell culture, rabbit model 
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INTRODUCTION 
 
Diseases in the posterior segment of the eye, such as age-related macular degeneration and 
diabetic retinopathy, affect the ocular function of over 8 million people in the USA alone
1-2
. 
These disorders are the most common causes leading to permanent vision loss in the 
industrialized countries. They are currently treated with instruments that require the visual 
and tactile perception of a surgeon. The surgical skills required are at the limits of human 
capabilities, and many retinal treatments risk permanent damage to the retina. Furthermore, 
accessibility within the eye is limited by instrument tethering and design
3-5
. Minimally- 
invasive, wirelessly controlled and powered microrobots
6
 are alternatives proposed for use in 
ocular medicine. Injected suturelessly into the eye
5
 [Figure 1(A-B)], they can be precisely 
steered with 5 degrees of freedom using external magnetic fields generated by a magnetic 
manipulation system
4
. The system controls the forces and torques that the microrobot applies 
during surgery, and the microrobot’s location is tracked visually through the pupil. The 
microrobot can precisely access regions of the eye that conventional tools cannot reach. 
 Several potential ophthalmic applications, such as fluorescent dye-based oxygen sensing
7
 
for diagnosis of retinal hypoxia, retinal vein puncturing
8-9
 for precisely targeted injections, 
intravitreal micromechanical measurements
10
, and drug delivery
11-12
 for retinal diseases, have 
been demonstrated using microrobots. Unlike conventional ophthalmic drug-delivery 
procedures (i.e., with tablets, eye drops, and lotions) that must be administered frequently to 
maintain the required therapeutically relevant tissue levels of the drugs, implantable steerable 
microrobots offer an alternative strategy as therapeutic reservoirs. Drugs can be released 
directly to the target during an extended period while minimizing possible side effects to 
surrounding tissues. The drug can be encapsulated
9,11
 inside the microrobot or included on a 
multi-layered functional surface
12
. 
 4 
 In ophthalmic applications, the microrobot can be implanted in the posterior segment of 
the eye in the proximity of ocular structures needing treatment/diagnosis. A targeted drug-
delivery
4,11-12
 application to treat age-related macular degeneration requires implantation. 
Vessel-targeted injections with thrombolytics for central retinal artery and vein occlusions are 
further potential applications. The microrobots can be steered and oriented during a 
procedure using a magnetic manipulation system
4
 designed for the microrobots. They can be 
implanted in a desired location. After implantation the microrobots can be controllably 
retrieved from the eye
5 
using the same manipulation system. The system is capable to align 
them with and maneuver them toward a custom-made ‘reverse’ injector with a magnetic 
shaft
5
, and the shaft can be used to pull the microrobot inside the injector. A critical factor for 
the success of these new therapies is the biocompatibility of the microrobots, which is a 
function of shape, size, the physical, chemical and surface properties of the employed 
materials, the interaction of the microrobots with specific regions of the eye, the presence of 
an ocular immune response,  and duration of the interaction.  
 Progress on ocular biomaterial research is demonstrated by the widespread use of contact 
lenses, and the frequent use of intraocular lenses implanted in cataract surgeries. This has 
spurred research on biomaterials for implantable devices such as glaucoma filtration devices, 
scleral buckles, and keratoprostheses. In contrast, research on biomaterials for the posterior 
segment is still in early development as posterior segment implants themselves are a 
relatively new phenomenon
13
. Several metals and polymers are used as an implant material 
and as an implant coating.  
 The typical metals used in ophthalmic surgery instruments are titanium and stainless steel, 
because their acute ocular toxicity is negligible
14
. Additionally, new suturing techniques in 
anterior segment surgery have used nitinol intraocular clips that have not demonstrated any 
short-term toxicity in mini-pig eyes
15
. Titanium tacks have exhibited long-term 
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biocompatibility in rabbit eyes and may provide a permanent and stable option for anchoring 
intraocular implants in the posterior segment
16
. In several medical applications, titanium 
coating provides superior surface adhesion properties and micro-surface smoothness in vitro 
and in vivo
16
. However, functionalization of these metals can be challenging. 
Gold
17-18
 (Au) is a good candidate for ocular implant coatings due to its nobility, inert nature, 
resistance against bacterial colonization, as well as its potential functionalizability. Used also 
as an adhesion layer, Au enables further electrodeposition of other functional coatings. 
 Two types of polymer materials, erodible and non-erodible, have been used in intraocular 
implants that are already on the market or close to commercialization. One of the most long-
standing implants, Ozurdex
19
, consists almost entirely of bioerodible poly(lactide-co-
glycolide) (PLGA). Although the by-products of bioerosion (water and carbon dioxide) are 
non-toxic, acidification during degradation is detrimental for biological function (i.e., protein 
delivery). The Retisert
20 
implant, approved by the FDA for treating uveitis, is composed of a 
combination of non-degradable poly(vinyl alcohol) (PVA) and non-erodible silicone 
elastomer held together by silicone glue. The Retisert implant therefore has to be surgically 
retrieved after implantation. Iluvien is a another non-degradable insert made from 
poly(imide) with PVA caps to control the rate of drug release
21
 and is in clinical use to treat 
diabetic macular edema.  
 New, better tunable and functionalizable polymers are needed for future ocular 
applications. Polypyrrole (Ppy) has well-established long-term biocompatibility with a 
variety of cell types (e.g., as neural prosthetics
22
). It is the best-characterized intrinsically 
conducting polymer due to its versatile and tunable properties, and also exhibits mechanical 
stability and ease of synthesis. Ppy can be prepared as a conformal functional coating onto 
microstructures of different shapes. Its surface properties can be electrochemically tuned due 
to its property of redox switching
23
.  
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 In this paper, cylindrical microrobots made of magnetic cobalt-nickel (CoNi) alloy 
(allowing magnetic manipulation), coated with Au and Ppy, are explored for their 
biocompatibility in ocular applications. The corrosion performance of the coated (Au and 
Ppy) and uncoated microrobots (as-prepared CoNi) is investigated. Hank’s balanced salt 
solution (HBSS) was used for modeling the corrosion properties of the vitreous to mimic its 
primary component. HBSS is a standard physiological solution, used as anterior eye chamber 
fluid replacement, as intraocular irrigation fluid and a typical model used in ophthalmic 
toxicology studies
24
. In vitro cell viability as determined by cell proliferation of NIH3T3 
fibroblasts was performed to investigate potential release of metal ions or leachables from 
coated and uncoated microrobots for implantation after 1 week of storage in solution. Finally, 
in vivo trials with coated microrobots [Figure 1(A-B)] were carried out inside the eyes of 
living New Zealand white rabbits with a follow-up of 49 days.  
 
MATERIALS AND METHODS 
 
Fabrication of the microrobots 
 
The fabrication of tubular microrobots [Figure 1(B)] is described in detail elsewhere.
9
 The 
outer diameter (OD) of all the microrobots was restricted to 300±10 µm to satisfy the size 
requirements of the inner diameter (ID) of the 23G needle used for sutureless injection into 
the ocular vitreous. Solid CoNi microrobots were fabricated on a Au wire (250 µm in 
diameter) to provide the electrical connection required in the electrochemical corrosion tests. 
Cell tests were carried out with similar microrobots. A CoNi layer 25 µm thick was deposited 
on the wire to obtain the final OD of 300 µm. For in vivo studies, the microrobots were 
fabricated on a thinner sacrificial aluminum wire (125 µm in diameter; pre-coated with 0.2-
µm-thick Au in bright electroless Au bath at 90°C for 12 min, Transene company, Inc., 
Danvers, MA, USA). The thinner wire allowed for preparation of sufficient magnetic 
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material (CoNi) for magnetic manipulation. Hence, CoNi 88 µm thick was electroformed on 
the wire to obtain the final OD of 300 µm. Subsequently, the aluminum wire was etched, and 
only the electrolessly prepared Au coating remained covering the hollow interior of the 
microrobot. Microrobots were then coated for the tests. Their surface after coating with Au 
and Ppy is shown in Figure 1(C-D), respectively.  
 
Preparation of the coatings 
 
Prepared as shown in Table 1, solid microrobots without coating (controls) and with coatings 
from two different materials (Au and Ppy) [Figure 2], were used in corrosion and in cell tests. 
The microrobots used in vivo had their outer surface coated with Ppy and their inner surface 
coated with Au (i.e., hollow interior used as a potential drug reservoir). The same coating 
methods were used as with the solid microrobots. The Au layer serving as a potential final 
coating or as an adhesive layer for further coatings was prepared using two methods. Au 
coating type I was prepared by electroless deposition by immersing an implant into a bright 
electroless Au bath (from Transene company, Inc., Danvers, MA, USA) at 90°C for 12 min. 
Au coating type II [Figure 1(C)] was prepared by electrodeposition in a Au bath with a 
formulation described by Jang et al.
25
 Both types, 0.2-µm-thick coatings, were compared in 
corrosion and in cell tests. The use of Au enabled subsequent electrodeposition of Ppy on the 
CoNi microrobots. 
 Ppy [Figure 1(D)] was galvanostatically electropolymerized on the Au-coated 
microrobots. In preparing the Ppy coating
23
, an electroplating bath containing 0.1 M sodium 
dodecylbenzene sulfonate (NaDBS) and 0.1 M pyrrole was used. A current density of 
1 mA·cm
-2
 was applied on the microrobot for 10 min to get a thickness of approximately 
3 µm. The microrobot served as the working electrode (WE) and a platinum-coated titanium 
plate as the counter electrode (CE), together with a reference electrode (RE). A double 
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junction Ag|AgCl RE was used with 3 M KCl inner solution and a 0.1 M NaDBS outer 
solution.  
 The microrobots with Ppy surfaces were cathodically doped to gain antibiofouling
23
 
properties for the cell and for the in vivo tests. Cathodic doping was performed in a  
0.1 M NaDBS aqueous solution with the same electrode arrangement employed in the Ppy 
electropolymerization. The doping was carried out by cyclic voltammetry (3 cycles; scan rate 
of 10 mV·s
-1
) between 0 V and -0.7 V. 
  
Corrosion tests 
 
HBSS (Sigma, H8264-500mL) was used to evaluate the corrosion properties of the 
microrobots’ materials and coatings. The electrochemical cell equipment used for the 
corrosion tests is presented in Supplementary material [Figure S1]. The cell filled with 100 
mL of HBSS was thermostated at body temperature (37°C). Each microrobot was immersed 
2 mm into the HBSS using a micropositioner (SmarAct GmbH, HCU-3D). Three electrodes 
were immersed into the HBSS (WE, CE, and RE). The microrobot was used as the WE. A 
platinum-coated helical titanium wire was used as the CE for applying a homogeneous 
electric field around the microrobot [see Figure S1]. The RE was a double-bridge (Ag | AgCl 
(3 M KCl)) filled with HBSS in the outer bridge. The samples were subject to an open-circuit 
potential (OCP) for 5 h in order to determine the steady-state potential. Then, 
potentiodynamic polarization tests were performed by scanning at a scan rate of 0.1 mV·s
-1
 
from 300 mV below the obtained OCP value toward more positive values up to 300 mV 
above the OCP. Between three and six replicas per microrobot type were tested. A paired t-
test with Bonferroni correction for the comparison of multiple groups was used to validate 
the significance (95% confidence level) of the differences between the microrobot types 
regarding their corrosion potential. The specimens were subjected to SEM imaging (Merlin 
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Zeiss), energy dispersive X-ray (EDX) and X-ray photoelectron spectroscopy (XPS) analysis 
after the corrosion tests. XPS analyses were carried out on a PHI 5500 Multitechnique 
System (from Physical Electronics) spectrometer, equipped with a monochromatic X-ray 
source (KAl line with energy of 1486.6 eV and 350 W). 
 
Fibroblast proliferation assay 
 
Prior to the experiments, the microrobots [Figure 2] were sanitized for >12 hours in 70% 
ethanol and were washed three times with phosphate buffered saline (PBS) containing 1% 
Penicillin/Streptomycin antibiotics (Biochrom A2212) in an Eppendorf tube. They were 
stored in 400 µL of PBS containing 1% Penicillin/Streptomycin as a release medium for one 
week at room temperature. NIH3T3 fibroblasts (ATCC-Number CRL-1658, ATCC, 
Manassas, VA), harvested from subconfluent monolayers, were incubated in 25 cm
2
 culture 
flasks at 37°C and 5% CO2. The growth medium (DMEM) included 10% heat-inactivated 
fetal bovine serum (Invitrogen 10270) and 1% Penicillin/Streptomycin. NIH3T3 fibroblast 
proliferation was characterized by the mitochondrial activity of living cells using a 
tetrazolium dye (MTT) based colorimetric assay as previously described in Sivaraman et al.
23
 
5000 fibroblast cells were seeded in 100 µL growth medium in a 96-well plate. On the next 
day 100 µL of PBS, in which the different types of microrobots had been stored for 7 days, 
was added for 24 hours prior to analysis. The cell proliferation was then normalized with the 
mitochondrial activity of the cells cultured in pure PBS with 1% Penicillin/Streptomycin (i.e., 
control). A minimum of 4 samples was used for in vitro cell experiments. The MTT assay is a 
common and standard assay to assess cell proliferation as readout for toxicity and is routinely 
performed with antibiotics in the test medium.
23,26
 Although it is generally possible to 
perform the assay without antibiotics, they were used in the first toxicity screening for 
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monitoring potential adverse effects of the microrobots reported here. The control group was 
therefore treated similarly with PBS containing 1% antibiotics and set to 100 % viability. 
 
In vivo rabbit experiments 
 
The microrobots were washed in an acetone bath, then in an isopropanol-ethanol (1:1) 
solution and finally in DI water prior to injecting into the in vivo rabbit eyes (healthy New 
Zealand white rabbits, 9 month-old female). The microrobots were subsequently autoclave 
sterilized. Prior to the injection the rabbits were anesthetized. Animal housing, anesthetic and 
surgical procedures, and post-procedure examinations were performed in laboratory animal 
facilities at the Vetsuisse Faculty, University of Zurich. 
 Two groups of rabbits were used (Groups A and B) with 6 individuals in each group. The 
rabbits in Group A, received a microrobot injected into a randomly assigned eye (referred to 
as Group A1). The fellow eyes of these rabbits served as internal controls (referred to as 
Group A0). Group B served as control group for the microrobot injections. Rabbits in Group 
B received a sham injection into a randomly assigned eye (referred to as Group B1). The 
fellow eyes of these rabbits served as internal controls (referred to as Group B0). 
 Sutureless injections into the rabbit eyes were carried out via a standard 23G needle 
through the pars plana of the ciliary body into the vitreous [see Figure 3]. Successful 
injections into the right eye were performed at the 10-11 o’clock position and into the left eye 
at the 1-2 o’clock position. The maximum distance between the injection site and internal 
limbus observed during injection was 1 mm. Preliminary ex vivo injection experiments in 
rabbit eyes obtained from slaughter demonstrated this distance as optimal to ensure safe 
insertion of the microrobots into the central vitreous while avoiding damage to critical tissues 
(e.g., lens and retina). In Group A1, the microrobots were injected using 0.1 mL hyaluronic 
acid (HA, Acrivet Biovisc 1.2%), which helped to push the robot away from the needle tip. 
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For each rabbit receiving an intravitreal microrobot, there was a control rabbit (Group B1) 
that received a sham-injection of 0.1 mL HA only, which was identical in all aspects other 
than the insertion of a microrobot. The non-injected eyes (i.e., fellow eyes) of the rabbits 
served as internal controls (Groups A0 and B0). Post-injection medications included 0.2 mg 
Buprenorphine (s.c., for analgesia during the first day), 5 mg/kg Enrofloxacin as antibiotic 
and 0.3 mg/kg BW Meloxicam for anti-inflammatory purposes for 10 days. The eyes were 
followed clinically for 49 days after implantation was performed. The microrobots were 
manipulated (i.e., rotated and moved a maximum distance of their body length) at 28 days 
after implantation and the effect of robot manipulation was observed. 
 The condition of the eyes was examined for inflammatory-response related changes (see 
Supplementary material: Protocol for ophthalmic examination pre- and post-implantation of 
intravitreal steerable inserts). Slit lamp biomicroscopy of the anterior segment using a hand-
held slit lamp (Kowa SL-15) with 10/16x magnification was used. Indirect ophthalmoscopy 
of the posterior segment (i.e., vitreous, retina, and optic nerve) was performed using a Heine 
Omega 200 indirect ophthalmoscope and 20, 30, and 40 diopter condensing lenses. 
Tonometry was used to determine intraocular pressure (IOP) using a calibrated rebound 
tonometer (TonoVet). A modified McDonald-Shadduck
27
 score system (see Supplementary 
material: Ocular irritation scoring scale based on modified McDonald-Shadduck score 
system) was used to grade inflammatory changes in the anterior and posterior segment. 
Ophthalmic examinations were carried out as described above when the animals arrived at 
the research facility, as well as one day prior to the planned intervention with the microrobot 
implantation or sham injections. Follow-up examinations were organized every day during 
the first three days after the injection, and subsequently, once every week until euthanasia 
(day 50). Immediately after euthanasia the eyes were surgically removed and placed in a 
modified Karnovsky’s fixative (Paraformaldehyde 2%, Glutaraldehyde 2.5% in 0.1M Sodium 
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Phosphate buffer) for 24 hours at room temperature. The eyes were then placed in a 0.1M 
NaP buffer solution for shipment to the Comparative Ophthalmic Pathology Laboratory of 
Wisconsin (University of Wisconsin-Madison, USA) where the eyes were examined 
histopathologically by light microscopy. 
 Data were evaluated using descriptive statistics. No statistical comparisons were 
performed since calculations with non-continuous longitudinal datasets require a relatively 
high number of subjects for adequate power. This was not the case, nor the objective in this 
study.  
 The Zurich cantonal Swiss Veterinary Office approved all the protocols used (i.e., 
treatment, monitoring, animal housing) based on the Swiss decree on animal protection. The 
protocols are in accordance with the principles and policies in the Animal Welfare Act and 
NIHGuide for Care and Use of Laboratory Animals. 
 
RESULTS 
This section presents the results from the corrosion tests, fibroblast cell tests, and in vivo 
rabbit experiments performed to explore biocompatibility and suitability of the microrobots 
for implantation. 
 
Corrosion tests 
 
Figure 4 shows typical potentiodynamic polarization curves for coated and uncoated 
microrobots. Table 2 presents statistics on corrosion potential Ecorr and corrosion current 
density jcorr determined by Tafel analysis. The corrosion potential Ecorr of Ppy-coated 
microrobots was significantly higher than that of Au coated (type I) or uncoated microrobots 
(p-values < 3.7·10
-2
), which indicates a more “noble” nature of the surface reacting with 
HBSS. Also, Ecorr for Au coating type II was significantly higher than that of the uncoated (p-
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value=3.5·10
-2
). However, the difference between Ecorr of Au coating type I and II (p-
value=6.3·10
-1
) was statistically insignificant at 95% confidence level. All microrobots had 
minimal jcorr (i.e., the jcorr values were less than 3 μA·cm
-2
; the mean jcorr values were less 
than 2 μA·cm-2). The jcorr values indicated that there was a lesser release of ions from Au 
coating type II than from uncoated microrobots. NB: Ppy is a conducting polymer, hence 
current measured (i.e., corresponding current density 4.83±0.76 μA·cm-2) is a sum of 
corrosion currents and doping/undoping currents between the microrobot and the HBSS [see 
(*) in Table 2].  
  The surface of the microrobots was analyzed by SEM following the potentiodynamic 
polarization tests. All the microrobots preserved their integrity [Figure 5(A)], although some 
localized features were observed. In particular, a microcracked surface was noticed for the 
Ppy-coated microrobots [Figure 5(D)]. The cracks typically occur due to the Ppy doping 
process.
23
 Na, Ca, Cl, O and P elements originating from the HBSS solution residue [see 
Figure 5(B)] were typically detected in the corresponding EDX patterns (data not shown). 
Despite the aforementioned features, the surface of the microrobots did not show any traces 
of Co and Ni, as proven by XPS analyses (Figure SX). Hence, the Au coatings perfectly 
sealed the CoNi body from direct contact with HBSS medium. Indeed, the survey spectrum 
of the Ppy-coated microtubes was very similar to that of the as-prepared material.
23
 C and O 
were the main elements detected by XPS at the uttermost surface in both Au (type I and type 
II)- and Ppy-coated microtubes. Additionally, N was detected in the latter. Na, Ca and P were 
detected in small amounts in the Au-coated microtubes by XPS as well. These were likely 
coming from the HBSS solution. The oxygen content in the uncoated microrobots was found 
to be low ( 4 wt%) by EDX, indicating that the CoNi alloy did not oxidize extensively. 
Actually, the Co/Ni ratio remained the same in both uncoated and coated robots (38 at% Co, 
Comentari [MP1]: I prepared the 
figure in case we want it to include it 
as S.I. I would do it. 
Comentari [MP2]: Not linked yet. 
 14 
62 at% Ni). This indicates that no preferential release of Co or Ni ions took place in the 
former despite the absence of any protective coating.  
 
In vitro fibroblast viability 
 
NIH3T3 fibroblast viability was determined by tetrazolium conversion that monitors the 
mitochondrial activity as an indication of living cells. Cell proliferation relative to control 
[Figure 6] was indistinguishable for uncoated microrobots, coated microrobots, and the 
control samples. The positive viability data gained from the in vitro cell culture assay were 
the motivation to perform in vivo biocompatibility trials in living rabbit eyes.   
 
In vivo rabbit experiments 
 
A Ppy-coated microrobot was injected with 0.1 mL HA into the ocular posterior segment 
(vitreous) of one randomly assigned eye in six healthy female New Zealand white rabbits 
(Group A1) [Figure 7]. Six more rabbits received a sham injection of 0.1 mL HA alone 
(Group B1). The posterior lens capsule was inadvertently damaged during the injection 
procedure in the first two eyes receiving a microrobot (Group A1) and in the first two eyes 
receiving a sham injection (Group B1). As a direct result of the lens capsule laceration a focal 
cataract developed in all of these four eyes. Only minimal inflammatory changes that are 
potentially related to the lens capsule ruptures were observed clinically and 
histopathologically. No study-related clinical or histopathologic abnormalities were observed 
in any of the fellow eyes not receiving injections (Groups A0 and B0). Clinically, eyes 
receiving HA sham injections (Group B1) showed mild inflammatory changes, which 
subsided within the first 2 weeks after injection [Figures 8]. Histopathology revealed a 
minimal limbal lymphoplasmacytic episcleritis in the vicinity of the injection site, which is a 
sign of very mild, local injection procedure related inflammation in these eyes [Figure 9].  
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 During the first week after injection, eyes receiving microrobots (Group A1) exhibited 
mild inflammatory changes [Figures 8(A-B)] similar to those observed in the eyes receiving 
HA sham injections [Figures S2(A-C) in Supplementary material]. The changes in the 
anterior part of the eye predominated and were interpreted to be a result of the injection 
procedure rather than the HA, since HA is a natural part of the vitreous. Inflammatory 
changes in the posterior segment of five out of six eyes receiving microrobots appreared 
(preretinal cell infiltrates and optic neuritis) or significantly increased (vitreal cells) during 
the second week after microrobot implantation [Figures 8(B) and S2(C)]. One eye had an 
optic nerve inflammation [Figure 10(A)]. A second eye had a complete and permanent 
detachment of the retina [Figure 10(B)]. These two eyes did not respond to light. A partial 
retinal detachment occurred in four more eyes, which was temporary in three eyes and 
permanent for the study duration in one. A tear or hole in the retina was observed clinically in 
two eyes. Such ocular changes were not observed in any of the control groups [Figures 
S2(C)]. No obvious changes were seen on microrobot surface prior to euthanasia [Figures 
S3(A-B)], however, a microscopic part of detached Ppy coating could be observed on one of 
the microrobots [Figures S3(C)].  
 By the end of the follow-up, histopathologic studies confirmed that the inflammation was 
accompanied by the presence of vitreous traction bands (n=3) [Figure 11(A)], retinal 
wrinkling/folding (n=3) [Figure 11(B)], retinal tear (n=2), retinal detachment (n=2) [Figure 
11(C)], retinal atrophy (n=3), or optic neuritis (n=1). Histopathologic sections also 
demonstrated multinucleated giant cells with phagocytosed brown foreign material in one of 
the rabbit eyes [Figure 11(D)]. The microrobot manipulation did not cause a significant 
increase of inflammatory changes apart from increased scores for conjunctival congestion 
and iris changes detected during the three following days [Figures 8(A) and S2(A-B)]. 
However, the level of inflammation in the vitreous had already reached a significant level by 
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that time [Figures 8(B) and S2(C)]. 
 
DISCUSSION 
  
Steerable ophthalmic microrobots are envisioned in ocular applications that require 
implantation. Coated (Au and Ppy) and uncoated (as-prepared CoNi) microrobots were 
investigated for their corrosion properties and for cell viability. The corrosion current density 
values as measured by potentiodynamic polarization were minimal (i.e., jcorr <3 μA·cm
-2
 for 
uncoated and Au coated; ND: current density of Ppy <5.5 μA·cm-2 includes doping/undoping 
currents). The corrosion potentials showed a trend consistent with the intrinsic nobility of the 
materials. Also, galvanic pairs between the CoNi alloy and the nobler Au layer that could 
cause severe oxidation of the CoNi material in the coated microrobots were not observed. 
This result suggests that Au (type I and II layers) homogeneously coats the CoNi alloy 
surface and exerts some sealing effect [Figure 5(C)].  
 NIH3T3 fibroblasts cultured in solution, in which coated or uncoated microrobots were 
stored for 7 days, were viable and proliferated normally. This finding indicates that no 
cytotoxic compounds were released from the microrobots into the supernatant after 7 days in 
solution. This result is consistent with the low corrosion current densities determined by 
electrochemical corrosion analyses. 
 In vivo tests with implantation in rabbit eyes were performed using Ppy-coated implants. 
The presence of significant inflammatory responses after the second week following injection 
can be interpreted to demonstrate the unsuitability of the microrobots for long-term 
implantation. A cracked Ppy surface [Figure 5(D)] used to enhance antibiofouling 
properties
23
, enlarges the surface area in ocular contact, and therefore increases the risk of 
releasing potentially harmful sulfonate ions stabilized within the Ppy structure. Also, the 
presence of phagocytosed brown foreign material within multinucleated giant cells in one of 
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the rabbit eyes could indicate an inflammatory reaction to released Ppy [Figure 11(D)], even 
though the Ppy has exhibited biocompatibility on surface
23
. Rabbit eyes have been found 
among the most sensitive in vivo models
28-29
. Therefore, irritation of rabbit eyes can have a 
contribution to the reactions. The absence of significant inflammatory responses during the 
entire first week following injection motivates to continue investigating coated microrobots 
for implantation. Whether the uninflamed state of the eyes can be preserved with timely 
removal of the microrobots needs to be confirmed in an implantation−explantation study set-
up. A careful in vivo biocompatibility characterization should be carried out if Ppy is 
intended for an ophthalmic application. The presented results provide valuable information 
for those who work on implant technology and biocompatibility. The future capability for 
microrobot implantation can realize the potential to enable a new generation of surgical
5,8-9
, 
targeted drug delivery
4,9,11-12
 and diagnostic
7
 techniques involving implantation in the 
posterior segment of the eye.  
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FIGURES 
 
Figure 1. A: A Ppy-coated microrobot to be injected suturelessly via a 23G needle into a living rabbit eye. The microrobot 
is loaded into the needle using suture forceps with flat tying platform. The photograph is rotated and mirrored for clarity. B: 
The SEM image shows a typical cylindrical CoNi microrobot as prepared. The inset shows a magnified detail of one end. 
Microrobots were coated with Au and with Ppy, which are shown in the following SEM images. C: Au coating on the 
surface of a CoNi microrobot. D: Ppy coating prepared on a Au-coated microrobot. Imaging was carried out using a Zeiss 
Ultra 55. 
 
 
Figure 2. The cross-sectional view of a solid microrobot that is coated with Au and Ppy.   
 
Figure 3. A: Pars plana injection with 23G needle placement 1 mm peripheral to the internal limbus. A precise needle 
placement is required to prevent damage to adjacent tissues. B: Visualization of the needle position within the vitreous 
cavity through the pupil. C: Ejection of a microrobot from the needle tip: 0.1 mL of HA was used to push the microrobot out 
of the needle tip. D: Successful placement of a microrobot in the center of the vitreous after retraction of the needle. 
 
 
Figure 4. Tafel plots of the microrobots tested in HBSS medium: uncoated CoNi surface (as prepared), electrodeposited Au 
surface (Au), and electrodeposited Ppy surface (Ppy).  
 
 
Figure 5. The SEM images shown were taken after the corrosion tests of a Au (type I) coated CoNi microrobot, shown in A. 
The zoomed details of the external surface for uncoated (B), Au (type I) coated (C), and Ppy/Au-coated (D) microrobots. 
 
 
Figure 6. Mean values of cell proliferation relative to control with SDs in error bars (n>4 samples for each microrobot type; 
7 as-prepared microrobots with a CoNi surface, 4 Au-coated type II microrobots, and 8 Ppy-coated microrobots). 100% 
corresponds to the mean proliferation of the cells in the PBS solvent referred to as control. 
 
  
Figure 7. Two typical images from the rabbit eyes one day after injection. A: A microrobot placed in the central part of 
the vitreous. B: A microrobot placed in the posterior part of the vitreous adjacent to the retina. 
 
 
Figure 8. Inflammatory changes observed in microrobot-implanted rabbit eyes (n=6). A: General inflammatory changes in 
the anterior segment of the eye. B: Inflammatory changes in the posterior segment of the eye. The time point t0 is baseline, t1 
indicates 4h after microrobot injection, and t2 indicates 4h after microrobot manipulation. Remark: ‘max = 1-4’ refers to the 
maximal clinical scores assigned to the various clinical variables that were scored according to the ‘Ocular irritation scoring 
scale based on modified McDonald-Shadduck score system (Altmann et al.27)’, which is provided in Supplementary 
material. 
 
 
Figure 9. Mild limbal lymphoplasmacytic episcleritis in the vicinity of the injection site observed in all eyes receiving sham 
injections. This is a sign of very mild, local injection procedure-related inflammation in these eyes. Hematoxylin and eosin 
(H&E) histopathology stain (Image courtesy R.R.Dubielzig, COPLOW). 
 
 
Figure 10. A: (1) Baseline examination one day prior to microrobot injection. (2) Optic neuritis at 14 days post microrobot 
injection in the same eye as (1). Note the dilation of pre-existing blood vessels on and around the optic nerve head compared 
to the situation in the same eye at the baseline examination. B: Complete retinal detachment and optic neuritis at 28 days 
post microrobot injection. Blood vessel dilation and formation of new blood vessels are visible at the location of the optic 
nerve head. The detached retina can be observed as folded membranous structure that originates at the optic nerve head and 
fans out towards the periphery. The injected microrobot is visible at the top left side of the image. 
 
 
Figure 11. All images demonstrate histopathologic changes in eyes post microrobot injection (Images courtesy 
R.R.Dubielzig, COPLOW). A: Macroscopic image of a hemisected eye with a microrobot (black linear object) embedded in 
the vitreous behind the lens. The lens is yellow as a result of the fixative used to prepare the eye for histopathology. A vitreal 
traction band extends from the retina towards the microrobot (black arrow). B: Complete retinal detachment (black arrow). 
The optic nerve head is indicated by the red arrow. The ocular lens is visible as oval structure at the top of the image. H&E 
histopathology stain. This is the same eye as in Figure 10(B). C: A vitreal traction band (black arrow) at its point of 
attachment to the retina below. Retinal folds are visible on the right side of this image (red arrow). Periodic acid–Schiff 
(PAS) histopathology stain. D: Brown foreign material (black arrow), potentially Ppy coating, in a multinucleated giant cell. 
(H&E histopathology stain). 
